In the era of precision medicine, the efficacy of anti-EGFR agents in RAS wild-type patients and anti-PD-1 immunotherapies in patients with MMR deficiency or high MSI are well established [50,51,52,53]. Here, EGFR is linked to mismatch repair cancer syndrome 1.